Research: How are traditional alcohol brands adjusting RTD formulations for GLP-1 users?

RTD Formulation Adjustments for GLP-1 Users

The rapid rise of glp-1-medications (such as Ozempic and Wegovy) has triggered a structural reset across the global beverage and alcohol industry. Originally developed for diabetes management, these therapies profoundly suppress appetite and alter the brain’s reward pathways, leading to a documented reduction in alcohol cravings [4], [5]. Studies indicate that up to 45.3% of GLP-1 patients who previously consumed alcohol regularly reported a drop in consumption [5].

To maintain market share and relevance, traditional alcohol brands and producers of adult-soft-drinks are actively redesigning their Ready-To-Drink (RTD) portfolios. This transition involves modifying sweetener profiles, adding functional ingredients, adjusting portion sizes, and rethinking multi-beverage-strategy execution to align with the metabolic and lifestyle shifts of the-flexitarian-consumer [1], [3].

Ingredient and Formulation Shifts

Transitioning from Traditional Carbohydrates

Historically, mainstream RTDs and hard seltzers relied heavily on fermented cane sugar, malted rice, or corn syrup to provide both alcohol content and flavor [11]. Because GLP-1 users prioritize blood sugar regulation and experience early satiety, these high-calorie, sugar-dense formulations are increasingly unappealing. Beverage producers are pivoting to alternative sugars and non-nutritive sweeteners that do not trigger insulin spikes [2].

Prominent substitute sweeteners include:

• Allulose: A rare sugar that behaves similarly to traditional sucrose in processing but contains 90% fewer calories and does not significantly impact blood glucose [2].
• Erythritol & Xylitol: Sugar alcohols (polyols) that maintain zero or negligible glycemic indices. Xylitol offers sweetness parity with sugar but at 40% fewer calories [2].
• Stevia and Monk Fruit: Plant-derived, high-intensity sweeteners favored for “clean label” formulations [2], [6].

Sweetener Blending and Taste Parity

Achieving taste-parity with full-sugar equivalents requires complex blending technologies. Research indicates that using single artificial sweeteners can lead to off-notes or bitter aftertastes; therefore, formulators often utilize equi-sweet blends (e.g., sucralose mixed with acesulfame-K or aspartame) to closely mimic the sensory profile of sucrose [8]. However, traditional artificial sweeteners like aspartame and sucralose face scrutiny regarding long-term stability in liquid formats and consumer pushback over chemical synthesis [8].

Integration of Functional Additives

Because GLP-1 users often experience side effects such as nausea, dehydration, and fatigue, beverage formulations are increasingly prioritizing wellness through functional-premiumization.

• Hydration & Satiety: Formulations are pivoting toward hydration-focused, low-carbonation profiles. High levels of carbonation can exacerbate GLP-1-induced bloating, leading brands to experiment with still or lightly sparkling formats [3], [13].
• Adaptogens & Nootropics: To replicate the social and relaxing effects of alcohol without the metabolic penalty, brands are substituting ethanol with adaptogens. Ingredients such as Ashwagandha (for stress response), L-theanine (for calm focus), and Lion’s mane (for cognitive clarity) are becoming staples in GLP-1-friendly RTD mocktails [13], [14].

Packaging and Go-to-Market Strategy

Portion Control and Shelf Redesign

The reduced caloric intake of GLP-1 patients has led to a demand for portion-controlled packaging. Brands are shifting away from large-format cans (e.g., 16oz or 19.2oz) toward smaller, sleek 8oz to 12oz formats that align with reduced gastric capacity [3].

Retailers are mirroring this shift by redesigning physical shelf logic around “metabolic alignment” and satiety [1]. This requires alcohol brands to engage in strategic visual-merchandising-beverage and cross-category placement, sometimes positioning functional adult beverages in pharmacy channels or health-food aisles rather than traditional liquor aisles [5].

Strategic Partnerships

Alcohol conglomerates are increasingly seeking cross-ecosystem partnerships. Brands are moving to adopt clinical research methods to formulate medical-grade functional beverages and are looking to integrate into doctor-recommended weight-loss programs. The pharmacy channel is emerging as a critical point of sale, leveraging retail-media-networks to hyper-target shoppers purchasing GLP-1 prescriptions with complementary hydration and functional beverage options [1], [5].

Contradictions and Regulatory Gaps

Several regulatory and biological contradictions complicate the formulation of GLP-1-friendly RTDs:

• WHO Guidelines vs. Industry Trends: While beverage companies heavily rely on non-sugar sweeteners (NSS) like aspartame, sucralose, and stevia to cut calories, the world-health-organization-who has officially advised against using NSS for weight control, citing a lack of long-term metabolic benefits [10]. (Note: WHO guidelines exempt sugar alcohols/polyols from this classification [10]).
• Gastrointestinal Compounding: Formulations relying heavily on sugar alcohols like erythritol can cause digestive distress when consumed in large quantities [2]. Because GLP-1 therapies inherently cause delayed gastric emptying and nausea [13], RTDs high in sugar alcohols may unintentionally compound severe gastrointestinal discomfort for these specific consumers.
• The Diet Soda Paradox: As explored in the-diet-soda-paradox, while some studies claim artificial sweeteners promote beneficial short-chain fatty acid (SCFA) producing gut bacteria [7], these studies are heavily scrutinized for deep financial ties to the food and beverage industry [7]. Meanwhile, the fda strictly manages the Acceptable Daily Intake (ADI) of these ingredients [6], [9], forcing brands to navigate fragmented definitions of what constitutes a “healthy” sweetener.

Suggested Additional Sources

To fully map this trend within the closed-loop-ecosystem-beverage, future research should target:

• Corporate Earnings Transcripts: Investigate Q3/Q4 earnings calls from major players like asahi-group-holdings, diageo, and anheuser-busch-inbev for explicit mentions of RTD reformulation R&D expenditures linked to GLP-1 adoption.
• Basket-Level Scanner Data: Locate basket-level-scanner-data (via circana or nielseniq) to track the exact cross-purchasing velocity between pharmacy-filled GLP-1 prescriptions and specific functional RTD SKUs.
• Clinical Substantiation: Identify peer-reviewed studies directly measuring the pharmacokinetic interactions between glp-1-medications and high-dose adaptogens commonly used in alcohol alternatives.

References

1. GLP-1 shifts alcohol market dynamics | EY - US — ey.com
2. GLP-1 Friendly Alternative Sugars: The Sweet Truth — stcharlestrading.com
3. How GLP-1 is Impacting Pharma — and the Food & Beverage Aisle — clarkstonconsulting.com
4. GLP-1s show promise in treating alcohol and drug addiction | Endocrine Society — endocrine.org
5. GLP-1 drugs stir change in the beverage industry | AlixPartners — alixpartners.com
6. Assessing the Health Impact of Artificial Sweeteners — ift.org
7. New Study: Artificial Sweeteners May Help with Weight Loss — eatingwell.com
8. The Sweetness Technology of Sugar Substituted Low-Calorie Beverages — gavinpublishers.com
9. Aspartame and Other Sweeteners in Food - FDA — fda.gov
10. WHO advises not to use non-sugar sweeteners for weight control in newly released guideline — who.int
11. The hard truth about hard seltzer: It’s not as ‘healthy’ as you may think - PhillyDietitian - Philly Dietitian — phillydietitian.com
12. Complete GLP-1 Diet Guide (2026) — Clean Eatz Kitchen — cleaneatzkitchen.com
13. Your GLP-1 Diet Guide: What to Eat & Avoid — minglemocktails.com
14. Your GLP-1 Diet Guide: What to Eat & Avoid — minglemocktails.com